Translational crossroads for biomarkers

Robert C. Bast, Hans Lilja, Nicole Urban, David L. Rimm, Herbert Fritsche, Joe Gray, Robert Veltri, George Klee, Andrew Allen, Nam Kim, Steven Gutman, Mark A. Rubin, Andrew Hruszkewycz

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute-supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.

Original languageEnglish (US)
Pages (from-to)6103-6108
Number of pages6
JournalClinical Cancer Research
Volume11
Issue number17
DOIs
StatePublished - Sep 1 2005
Externally publishedYes

Fingerprint

Biomarkers
National Cancer Institute (U.S.)
Industry
United States Food and Drug Administration
Tumor Biomarkers
Early Detection of Cancer
Ovarian Neoplasms
Disease Progression
Prostatic Neoplasms
Research Personnel
Breast Neoplasms
Technology
Education
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bast, R. C., Lilja, H., Urban, N., Rimm, D. L., Fritsche, H., Gray, J., ... Hruszkewycz, A. (2005). Translational crossroads for biomarkers. Clinical Cancer Research, 11(17), 6103-6108. https://doi.org/10.1158/1078-0432.CCR-04-2213

Translational crossroads for biomarkers. / Bast, Robert C.; Lilja, Hans; Urban, Nicole; Rimm, David L.; Fritsche, Herbert; Gray, Joe; Veltri, Robert; Klee, George; Allen, Andrew; Kim, Nam; Gutman, Steven; Rubin, Mark A.; Hruszkewycz, Andrew.

In: Clinical Cancer Research, Vol. 11, No. 17, 01.09.2005, p. 6103-6108.

Research output: Contribution to journalArticle

Bast, RC, Lilja, H, Urban, N, Rimm, DL, Fritsche, H, Gray, J, Veltri, R, Klee, G, Allen, A, Kim, N, Gutman, S, Rubin, MA & Hruszkewycz, A 2005, 'Translational crossroads for biomarkers', Clinical Cancer Research, vol. 11, no. 17, pp. 6103-6108. https://doi.org/10.1158/1078-0432.CCR-04-2213
Bast RC, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J et al. Translational crossroads for biomarkers. Clinical Cancer Research. 2005 Sep 1;11(17):6103-6108. https://doi.org/10.1158/1078-0432.CCR-04-2213
Bast, Robert C. ; Lilja, Hans ; Urban, Nicole ; Rimm, David L. ; Fritsche, Herbert ; Gray, Joe ; Veltri, Robert ; Klee, George ; Allen, Andrew ; Kim, Nam ; Gutman, Steven ; Rubin, Mark A. ; Hruszkewycz, Andrew. / Translational crossroads for biomarkers. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 17. pp. 6103-6108.
@article{59bf346a58a34ed7b138d1b00287f888,
title = "Translational crossroads for biomarkers",
abstract = "A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute-supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.",
author = "Bast, {Robert C.} and Hans Lilja and Nicole Urban and Rimm, {David L.} and Herbert Fritsche and Joe Gray and Robert Veltri and George Klee and Andrew Allen and Nam Kim and Steven Gutman and Rubin, {Mark A.} and Andrew Hruszkewycz",
year = "2005",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-04-2213",
language = "English (US)",
volume = "11",
pages = "6103--6108",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Translational crossroads for biomarkers

AU - Bast, Robert C.

AU - Lilja, Hans

AU - Urban, Nicole

AU - Rimm, David L.

AU - Fritsche, Herbert

AU - Gray, Joe

AU - Veltri, Robert

AU - Klee, George

AU - Allen, Andrew

AU - Kim, Nam

AU - Gutman, Steven

AU - Rubin, Mark A.

AU - Hruszkewycz, Andrew

PY - 2005/9/1

Y1 - 2005/9/1

N2 - A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute-supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.

AB - A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute-supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development.

UR - http://www.scopus.com/inward/record.url?scp=24344491449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344491449&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-2213

DO - 10.1158/1078-0432.CCR-04-2213

M3 - Article

VL - 11

SP - 6103

EP - 6108

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -